{
    "clinical_study": {
        "@rank": "65516", 
        "arm_group": [
            {
                "arm_group_label": "Anakinra", 
                "arm_group_type": "Experimental", 
                "description": "Anakinra 100 mg in 2 ml saline IA"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Saline 2 ml IA"
            }
        ], 
        "brief_summary": {
            "textblock": "This project investigates the relation between acute pain and local inflammation. Pain\n      reported by the patients for knee arthroscopy are compared with local changes in\n      inflammatory mediators by using microdialysis technique. Patients with moderate-to-severe\n      pain are included in a randomized placebo-controlled trial of anakinra given\n      intra-articularly."
        }, 
        "brief_title": "Effects of Intraarticular IL1-Ra on Pain and Inflammatory Mediators After Knee Arhroscopy", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Knee Injuries", 
        "condition_browse": {
            "mesh_term": [
                "Knee Injuries", 
                "Wounds and Injuries"
            ]
        }, 
        "detailed_description": {
            "textblock": "The effects of the recombinant IL-1 receptor antagonist anakinra both on acute pain and post\n      operative inflammation will be evaluated. On inclusion, pain intensity will be measured on a\n      five-point verbal rating scale (0= no pain, 1=mild pain, 2=moderate pain, 3=severe pain, and\n      4=intolerable pain), and on a visual analogue scale (0-100mm). VAS scale will be repeated at\n      20, 40, 60, 80, 100, 120, 140, 160, 180 and 200 minutes after inclusion / intervention. The\n      patients will also rate pain intensity during a 5 meters walk at 200 minutes (evoked pain).\n      The patient will rate pain at rest and evoked pain 24, 48 and 72 h after intervention."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Otherwise healthy patients (ASA 1 and 2) undergoing knee arthroscopy in general\n             anaesthesia.\n\n          2. Being informed about and willing to participate in the study -\n\n        Exclusion Criteria:\n\n          1. Pregnancy or lactation. Fertile women will be asked if they may be pregnant, and\n             offered a pregnancy test if there is doubt.\n\n          2. Established osteoarthritis or synovitis\n\n          3. Known intolerance to anakinra\n\n          4. Kidney failure (Creatinine clearance <30ml/min)\n\n          5. History of frequent infectious diseases or immunodeficiency\n\n          6. Heart failure\n\n          7. History of drug -or alcohol abuse\n\n          8. Participation in other synchronous clinical trials\n\n          9. Perioperative steroid treatment, perioperative paracetamol (12 hrs), NSAIDs (24 hrs)\n             or COX2-inhibitors (48 hrs).\n\n         10. Use of tourniquet for bloodless field\n\n         11. Strong preoperative pain (VRS \u22653)\n\n         12. Intolerable postoperative pain (VRS=4)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01997138", 
            "org_study_id": "anakinrapain1"
        }, 
        "intervention": {
            "arm_group_label": "Anakinra", 
            "intervention_name": "Anakinra 100 mg in 2 ml saline IA", 
            "intervention_type": "Drug", 
            "other_name": "Kineret"
        }, 
        "intervention_browse": {
            "mesh_term": "Interleukin 1 Receptor Antagonist Protein"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "pain, inflammation, surgery", 
        "lastchanged_date": "November 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Oslo", 
                    "country": "Norway", 
                    "zip": "0855"
                }, 
                "name": "Lovisenberg Diakonal Hospital"
            }
        }, 
        "location_countries": {
            "country": "Norway"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Intraarticular IL1-Ra on Pain and Inflammatory Mediators After Knee Arhroscopy -a Double Blind, Placebo Controlled Study Using Microdialysis Technique", 
        "other_outcome": {
            "description": "Selv reported side effect according to CRF", 
            "measure": "Side effects", 
            "safety_issue": "Yes", 
            "time_frame": "72h"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Norway: Norwegian Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Selv reported pain", 
            "measure": "Pain relief", 
            "safety_issue": "No", 
            "time_frame": "72h"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01997138"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Need for and consumption of resuce analgesic drug", 
            "measure": "Resuce analgesic drug consumption", 
            "safety_issue": "No", 
            "time_frame": "72h"
        }, 
        "source": "Oslo University Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "University of Oslo", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Lovisenberg Diakonale Hospital", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Oslo University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}